ClinicalTrials.gg

Program

lenvatinib

Also written as “Lenvatinib”, “E7080” and “HOPE”.

Its studies are mostly in Carcinoma, Hepatocellular · Melanoma · Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 4 companies.

Furthest: phase 4, since Jun 19, 201879 company-led studies, 3 open or runningNext primary completion: Oct 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai511 open or runningphase 4since Jun 19, 2018Jul 15, 2005none ahead
Merck261 open or runningphase 3since Jan 22, 2019Aug 3, 2016Oct 22, 2027phase 2 · NCT02861573
AGO Research11 open or runningphase 2since May 11, 2023May 11, 2023Oct 30, 2027phase 2 · NCT05903833
Merck KGaA, Darmstadt, Germany10 open or runningphase 1since Oct 4, 2021Oct 4, 2021none ahead

Also a collaborator on its studies: Ono Pharmaceutical, pharmabio-development-inc and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Jan 2, 2013.

  1. Mar 4, 2020Phase 4 study in Carcinoma, HepatocellularEisai · NCT04297254 · 50 enrolled · India
  2. Mar 9, 20202 phase 2 studies in MelanomaMerck · NCT04305054, NCT04305041
  3. Jun 9, 20202 phase 2 studiesMerck · NCT04428151, NCT04447755
  4. Dec 4, 20202 phase 3 studiesMerck · NCT04662710, NCT04676412
  5. Jan 7, 2021Phase 2 study in Carcinoma, Renal CellMerck · NCT04704219 · 160 enrolled · United States, Australia, Canada and more
  6. Jan 19, 2021Phase 3 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyMerck · NCT04716933 · 201 enrolled · China
  7. Feb 26, 2021Phase 3 study in Colorectal NeoplasmsMerck · NCT04776148 · 563 enrolled · United States, Argentina, Australia and more
  8. Apr 26, 2021Phase 3 study in Endometrial NeoplasmsMerck · NCT04865289 · 130 enrolled · China
  9. May 12, 2021Phase 3 study in MelanomaMerck · NCT04889118 · 131 enrolled · China
  10. Jun 9, 2021Phase 2 study in Small Cell Lung CarcinomaMerck · NCT04924101 · 122 enrolled · United States, Austria, Canada and more
  11. Jun 29, 2021Phase 3 study in Esophageal Squamous Cell CarcinomaMerck · NCT04949256 · 863 enrolled · United States, Argentina, Canada and more
  12. Oct 4, 2021Merck KGaA, Darmstadt, Germany's first study: phase 1 study in Central Nervous System NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05081180 · 17 enrolled · Canada, France, Germany and more
  13. Aug 29, 2022Phase 3 study in Squamous Cell Carcinoma of Head and NeckMerck · NCT05523323 · 112 enrolled · China
  14. May 11, 2023AGO Research's first study: phase 2 study in Vulvar NeoplasmsNew to AGO ResearchAGO Research · NCT05903833 · 42 planned · Germany

Ahead

  1. Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerMerck · NCT02861573
  2. Oct 30, 2027Primary completion: phase 2 study in Vulvar NeoplasmsAGO Research · NCT05903833

TargetBeta

“A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase ”NCIt, by rule
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
AxitinibrulePfizerphase 345
chiauranibruleChipscreen Biosciencesphase 315

Studies

The newest 60 of 79 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT05903833Vulvar Neoplasms · Germany2RecruitingAGO ResearchOct 30, 202742
NCT05523323Squamous Cell Carcinoma of Head and Neck · China3CompletedMerckAug 25, 2023112
NCT05081180Central Nervous System Neoplasms · Canada, France, Germany and more1TerminatedMerck KGaA, Darmstadt, GermanyFeb 11, 202617
NCT04949256Esophageal Squamous Cell Carcinoma · United States, Argentina, Canada and more3TerminatedMerckMay 8, 2025863
NCT04924101Small Cell Lung Carcinoma · United States, Austria, Canada and more2CompletedMerckJun 23, 2025122
NCT04889118Melanoma · China3CompletedMerckJan 18, 2023131
NCT04865289Endometrial Neoplasms · China3CompletedMerckOct 2, 2023130
NCT04776148Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedMerckSep 27, 2024563
NCT04716933Parkinson Disease 4, Autosomal Dominant Lewy Body · China3CompletedMerckAug 11, 2023201
NCT04704219Carcinoma, Renal Cell · United States, Australia, Canada and more2CompletedMerckJan 27, 2025160
NCT04676412Carcinoma, Non-Small-Cell Lung · China3CompletedMerckMay 19, 2021107
NCT04662710Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more3CompletedMerckOct 29, 2024895
NCT04447755Recurrence · United States, Argentina, Australia and more2CompletedMerckSep 16, 2022127
NCT04428151Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more2CompletedMerckMay 31, 2024408
NCT04305054Melanoma · United States, Argentina, Australia and more2CompletedMerckMay 18, 2026335
NCT04305041Melanoma · United States, Australia, France and more2CompletedMerckAug 25, 2025100
NCT04297254Carcinoma, Hepatocellular · India4CompletedEisaiJul 31, 202350
NCT04246177Carcinoma, Hepatocellular · United States, Australia, Brazil and more3TerminatedMerckAug 19, 2025480
NCT04199104Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more3CompletedMerckMay 30, 2023511
NCT04154189Osteosarcoma · United States, Australia, Austria and more2CompletedEisaiJun 22, 202281
NCT03976375Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedMerckAug 11, 2023422
NCT03898180Carcinoma, Transitional Cell · United States, Argentina, Australia and more3CompletedMerckJul 26, 2021505
NCT03884101Endometrial Neoplasms · United States, Argentina, Australia and more3CompletedMerckOct 2, 2023842
NCT03829332Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more3CompletedMerckMay 19, 2021623
NCT03829319Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more3CompletedMerckAug 11, 2023761
NCT03820986Melanoma · United States, Australia, Austria and more3CompletedMerckJan 18, 2023674
NCT03797326Triple Negative Breast Neoplasms · United States, Argentina, Australia and more2CompletedMerckOct 28, 2024611
NCT03776136Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more2CompletedMerckOct 11, 2023103
NCT03573960Thyroid Neoplasms · India4CompletedEisaiSep 4, 202550
NCT03516981Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more2CompletedMerckJun 13, 2025245
NCT03517449Endometrial Neoplasms · United States, Argentina, Australia and more3CompletedEisaiMar 1, 2022827
NCT03477175Solid Tumors · United States, Australia, Belgium and more2CompletedEisaiDec 21, 202340
NCT03433703Carcinoma, Hepatocellular · United States2TerminatedEisaiJan 7, 20198
NCT03418922Carcinoma, Hepatocellular · Japan1CompletedEisaiDec 28, 202230
NCT03245151Recurrence · United States, Canada2CompletedEisaiSep 30, 202264
NCT03173560Carcinoma, Renal Cell · United States, Australia, Canada and more2CompletedEisaiFeb 14, 2020343
NCT03009292Solid Tumor · China1CompletedEisaiDec 24, 201812
NCT03006926Carcinoma, Hepatocellular · United States, France, Italy and more1CompletedEisaiOct 31, 2019104
NCT03006887Carcinoma, Non-Small-Cell Lung · Japan1CompletedEisaiApr 15, 20206
NCT02966093Differentiated Thyroid Cancer (DTC) · China3CompletedEisaiJul 31, 2019151
NCT02953743Unresectable Hepatocellular Carcinoma (HCC) · China1CompletedEisaiJun 28, 201725
NCT02915783Neoplasm Metastasis · United States2CompletedEisaiNov 2, 202141
NCT02861573Metastatic Castration-Resistant Prostate Cancer2Active, not recruitingMerckOct 22, 20271,200
NCT02811861Carcinoma, Renal Cell · United States, Australia, Austria and more3Active, not recruitingEisaiAug 28, 20201,069
NCT02702388Thyroid Neoplasms · United States, Australia, Belgium and more2CompletedEisaiDec 12, 2019241
NCT02686164Neoplasms · United States1CompletedEisaiJan 4, 201751
NCT02657369Thyroid Carcinoma, Anaplastic · United States, Australia, France and more2TerminatedEisaiSep 26, 201834
NCT02579616Biliary Tract Neoplasms · Japan2CompletedEisaiNov 22, 201629
NCT02792829Healthy Volunteers · United States1CompletedEisaiAug 201460
NCT02723630Healthy Volunteers · United States1CompletedEisaiAug 201360
NCT02578316Lymphoma · Netherlands1CompletedEisaiJun 20106
NCT02501096Neoplasms · United States, Norway, Spain2CompletedEisaiAug 18, 2020357
NCT02454478Carcinoma, Renal Cell · Japan1CompletedEisaiMay 29, 20177
NCT02432274Neoplasms · United States, France, Germany and more2CompletedEisaiJul 18, 2019117
NCT02421042Hepatic Impairment · United States1CompletedEisaiJul 201214
NCT02199392P-glycoprotein · United States1CompletedEisaiJan 201215
NCT02199379Renal Insufficiency · United States1CompletedEisaiOct 201226
NCT02198170Healthy Volunteers · United States1CompletedEisaiJun 201118
NCT01877083Lung Neoplasms · United States, Hong Kong, Japan and more2CompletedEisaiFeb 3, 201625
NCT01761266Carcinoma, Hepatocellular · United States, Australia, Belgium and more3CompletedEisaiNov 13, 2016954

How it is read

Names in the registry

  • “Lenvatinib”, 72 entries
  • “lenvatinib”, 7 entries
  • “E7080”, 6 entries
  • “HOPE”, 2 entries
  • “E7080 capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.